Network Assisted Analysis of *De Novo* Variants Using Protein-Protein Interaction Information Identified 46 Candidate Genes for Congenital Heart Disease

Yuhan Xie¹, Wei Jiang¹, Weilai Dong², Hongyu Li¹, Sheng Chih Jin³, Martina Brueckner^{2,4}, Hongyu Zhao^{1,2,5*}

¹ Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA 06520

² Department of Genetics, Yale School of Medicine, New Haven, CT, USA 06520

³ Department of Genetics, Washington University School of Medicine, St Louis, MO, USA 63110

⁴ Department of Pediatrics, Yale University, New Haven, CT, USA 06520

⁵ Program in Computational Biology and Bioinformatics, Yale University, New Haven, CT, USA 06520

* To whom correspondence should be addressed:

Hongyu Zhao, Ph.D.

Department of Biostatistics, Yale School of Public Health, 60 College Street, New Haven, CT, 06520, USA

Email: hongyu.zhao@yale.edu

Abstract

De novo variants (DNVs) with deleterious effects have proved informative in identifying risk genes for earlyonset diseases such as congenital heart disease (CHD). A number of statistical methods have been proposed for family-based studies or case/control studies to identify risk genes by screening genes with more DNVs than expected by chance in Whole Exome Sequencing (WES) studies. However, the statistical power is still limited for cohorts with thousands of subjects. Under the hypothesis that connected genes in protein-protein interaction (PPI) networks are more likely to share similar disease association status, we develop a Markov Random Field model that can leverage information from publicly available PPI databases to increase power in identifying risk genes. We identified 46 candidate genes with at least 1 DNV in the CHD study cohort, including 18 known human CHD genes and 35 highly expressed genes in mouse developing heart. Our results may shed new insight on the shared protein functionality among risk genes for CHD.

Keywords

De novo variants, protein-protein interactions, congenital heart disease, network modeling

1 Background

Congenital heart disease (CHD) is the most common birth defect affecting ~ 1% of live births
and accounts for one-third of all major congenital abnormalities [1-3]. There is substantial
evidence that CHD has a strong genetic component [4]. Although it is estimated that
aneuploidies and copy number variations account for about 23% of CHD cases, few individual
disease-causing genes have been identified in published studies [5-8]. Therefore, the limited
knowledge on the underlying genetic causes poses an obstacle to the reproductive counseling
of CHD patients [9].

9

10 Whole Exome Sequencing (WES) studies have successfully boosted novel causal genes 11 identification for both Mendelian and complex disorders [10, 11]. To narrow down the pool of 12 candidate variants from WES, family-based studies have been conducted to scan for de novo 13 variants (DNVs) from parent-offspring trios. DNV studies have been shown to play an important 14 role in risk gene identification for CHD [1, 3, 5, 6, 12-15]. From the analysis of 1,213 CHD 15 parent-offspring trios, Homsy et al. identified greater burden of damaging DNVs, especially in 16 genes with likely functional roles in heart and brain development [12]. Recently, Jin et al. 17 inferred that DNVs in ~440 genes were likely contributors to CHD [5]. Despite these advances, it 18 remains challenging to capture the causal genes with only DNV data as CHD is very genetically 19 heterogeneous [6].

20

It is believed that genes interact with each other in biological processes and may jointly affect the disease risk through biological pathways. In recent studies on CHD, researchers reported significant enrichment of genes related to histone modification, chromatin modification, cilia function, transcriptional regulation, neural tube development, and cardiac development and enrichment in pathways including Wnt, Notch, Igf, HDAC, ErbB and NF-kb signaling [1, 3, 12, 14, 16]. These results suggest that considering functional relationships of genes through pathway-

27 level analyses may complement gene-level analyses and improve risk gene identification for28 CHD.

29

Recently, Nguyen et al. proposed a framework to conduct pathway-level analysis on
schizophrenia DNV data [17]. Their method is built on the extTADA framework and integrates
pathway information by multiplying a gene-set related term in the likelihood function. However,
this method requires curated pathways related to schizophrenia and treats genes as
exchangeable without considering gene-gene interactions. To characterize the functional
connectivity between genes, we can consider genes as a network by modeling the topology of
pathways.

37

38 Network-based approaches have been successful in prioritizing risk genes for downstream 39 analysis of Genome-Wide Association Studies (GWAS) and gene expression studies [18-20]. 40 Chen et al. [19] proposed a Markov Random Field (MRF) model to incorporate pathway 41 topology structure for GWAS. They showed that their method is more powerful than single 42 gene-based methods through both simulation and real data analyses. Following the idea of this 43 framework, Hou et al. [20] proposed a method that integrates co-expression networks and 44 GWAS results. By applying their method to Crohn's disease and Parkinson's disease, they 45 showed that their method could lead to more replicable results and find potential disease-46 associated pathways. More recently, Liu et al. adopted a similar idea as Chen et al. and Hou et 47 al. to analyze DNV data from WES studies [21]. Their framework, namely DAWN, combines 48 TADA p-values with estimated network from gene co-expression data. In their real data analysis 49 for autism, 333 genes were prioritized by integrating DNV summary statistics and expression 50 data from brain tissue. However, all of these above methods require summary statistics (Z 51 scores or p-values) from genetic association analysis as their input, which may not be provided 52 for DNV analysis results [22, 23]. In addition, it is difficult to apply DAWN directly to CHD

because of the lack of ideal co-expression data from relevant tissues (such as developmentalheart) for CHD.

55

56 As there is a limited number of co-expression data sets for human developmental heart, a 57 natural choice for network information would be human protein-protein interaction (PPI) 58 databases. There are multiple public sources of PPI network databases such as BioGRID [24]. 59 IntAct [25], DIP [26], MINT [27], and HPRD [28]. Most of network-based studies apply their real 60 data on two or more of the databases to obtain their results. Nonetheless, it is hard to check the 61 overlapping information between two PPI databases and interpret the divergent results. The 62 STRING [29] database provides a platform to resolve the above problems. It imports protein 63 association knowledge from physical interaction and curated knowledge from the 64 aforementioned PPI databases and other pathway information knowledge such as KEGG and 65 GO. In addition, it provides a score to measure the likelihood of interactions. Some studies have 66 used STRING in their post-association analysis for gene-based DNV studies and showed 67 significant enrichment of candidate CHD risk genes in the STRING PPI network [30, 31]. One 68 recent study [3] constructed a priority score based on canonical pathways and PPI networks 69 and identified 23 novel genes for CHD. These results suggest that incorporating PPI network 70 information from STRING may identify additional risk genes with more biological interpretability. 71

In addition, in the post-association analysis of CHD DNV analysis from our previous multi-trait method M-DATA [32], we found that the number of edges formed by candidate CHD genes (47 edges, green line in Fig 1A) identified by M-DATA multi-trait model (33 genes with false discovery rate (FDR) q-values < 0.1) is far larger than the upper tail of the empirical distribution sampled from 33 randomly selected genes in the STRING V11.0 database (score threshold: 400) for 10,000 times (Fig 1A). This suggests that the candidate CHD genes are highly enriched in terms of their interactions in the STRING database. To further illustrate that PPI information

79 may contribute to CHD gene discovery, we use the CHD result from M-DATA single-trait 80 analysis and use the result of autism as a comparison. Fig 1B shows the number of edges 81 formed by the top genes (ranked by FDR g-values) for CHD and autism from M-DATA single-82 trait model with a more stringent selection of PPI edges in the STRING database (score 83 threshold: 950), respectively. To compare with the number of edges formed by randomly 84 selected genes, we plot the 95% quantile of the empirical distribution sampled from random 85 genes in the STRING v11.0 database (score threshold: 950) for 10,000 times as a baseline. 86 When more than 25 top CHD genes are selected, the number of edges formed by these genes 87 is significantly more than that from randomly selected genes, whereas the number of edges 88 formed by the autism top genes did not differ much from randomly selected genes. This 89 suggests top genes in CHD tend to be neighbors in the STRING PPI network.





- 96 Motivated by the observation from Fig 1, we develop a **N**etwork assisted model for **D**e novo
- 97 Association Test using protein-protein interAction information, named N-DATA, to leverage prior

98 information of interactions among genes from the PPI network to boost statistical power in
99 identifying risk genes for CHD. In the following, we first introduce the inference procedure for
100 our model, and then demonstrate the performance of our method through simulation studies
101 and real data applications.

102

103 Methods

104 In this section, we introduce the statistical model for the proposed framework. The network

information in the PPI database is represented by an undirected graph G = (V, E), where

106 $V = \{1, ..., n\}$ is a set of *n* genes in the network, and

107 $E = \{ \langle i, j \rangle : i \text{ and } j \text{ are genes connected by the edges} \}$. The degree of a gene *i* is defined as the

108 number of direct neighbors (N_i) for gene *i* in the network and denoted as d_i . We denote the

latent association status of gene *i* with a disease of interest, e.g., CHD, as S_i , where $S_i = 1$ if

gene *i* is associated with the disease, $S_i = -1$ if gene *i* is not associated with the disease.

111 $S = \{S_1, ..., S_n\}$ are the corresponding latent states for genes in $V = \{1, ..., n\}$. The DNV count of 112 the cohort is defined as Y_i . To formalize the assumption that genes that have PPIs with risk 113 genes are more likely to be risk genes, we apply a nearest neighbor Gibbs measure [33] to 114 arrive at the following model:

$$P(S|\theta_0) \propto exp\left\{h\sum_{i\in V} I_1(S_i) + \tau_0 \sum_{\langle i,j\rangle\in E} (w_i + w_j)I_{-1}(S_i)I_{-1}(S_j) + \tau_1 \sum_{\langle i,j\rangle\in E} (w_i + w_j)I_1(S_i)I_1(S_j)\right\}$$
$$Y_i|S_i = -1 \sim \text{Poisson}(2N\mu_i)$$
$$Y_i|S_i = 1 \sim \text{Poisson}(2N\mu_i\gamma)$$
$$\theta_0 = (h, \tau_0, \tau_1); \theta_1 = \gamma,$$

115

where w_i is the weight for gene *i* and will be chosen based on the characteristics of the

117 network, $\theta_0 = (h, \tau_0, \tau_1)$ are hyperparameters related to the network. Specifically, h determines

118 the marginal distribution of S_i when all genes are independent i.e., $P(S_i = 1 | h, \tau_0 = \tau_1 = 0) =$ 119 $\frac{\exp(h)}{1 + \exp(h)}$. τ_0 and τ_1 characterize the prior weights of edges between non-associated genes and 120 associated genes, respectively. *N* is the sample size of the case cohort, μ_i is the mutability of 121 gene *i* estimated using the framework in Samocha et al. [34], and θ_1 (γ) is the relative risk of 122 the DNVs in the risk gene.

123

To reduce the computational burden from a fully Bayesian solution for maximizing the marginal likelihood, we propose an empirical Bayes method to estimate the parameters θ_0 and θ_1 , and the latent association status *S* by maximizing the pseudo conditional likelihood (PCLK) for *n* genes as follows

$$\mathsf{PCLK} = \prod_{i=1}^{n} f(Y_i | S_i, \theta_1) \operatorname{Pr}(S_i | S_{N_i}, \theta_0).$$

128 It has been shown that the estimator from the PCLK in a general Markov random field setting is 129 consistent under mild regularity conditions [19] [35]. When maximizing the PCLK, we can 130 estimate the hyperparameters θ_0 , θ_1 and latent status *S* iteratively.

131

- 132 We can obtain an empirical estimate for θ_0 by maximizing $\prod_{i=1}^{n} \Pr(S_i | S_{N_i}, \theta_0)$, which is
- 133 equivalent to maximizing the parameters in the following logistic regression model:

$$\operatorname{logit} \Pr(S_i | S_{N_i}, \theta_0) = h + \tau_1 X_{i1} - \tau_0 X_{i0},$$

where
$$X_{i1} = w_i \sum_{k \in N_i} I_1(S_k) + \sum_{k \in N_i} w_k I_1(S_k)$$
 and $X_{i0} = w_i \sum_{k \in N_i} I_{-1}(S_k) + \sum_{k \in N_i} w_k I_{-1}(S_k)$, $i = 1, ..., n$. To make sure the estimated θ_0 is finite, we can add a ridge penalty term $\lambda(h^2 + \tau_0^2 + \tau_1^2)$
to the likelihood function to solve the maximization problem by the Newton-Raphson's method
[36].

- 139 We then update the latent status *S* by maximizing the PCLK using the iterative conditional mode
- 140 method [35]. After we obtain the updated values θ_0 and S, we can estimate the hyperparameter
- 141 θ_1 by maximizing $\prod_{i=1}^n f(Y_i | S_i, \theta_1)$ by using the following closed-form expression:

$$\log L(\theta_1|Y) \propto \log \prod_{S_i=1} \exp(-2\mu N\gamma + Y_i \log \gamma)$$
$$\frac{\partial \log L(\theta_1|Y)}{\partial \gamma} = -\sum_{S_i=1} 2\mu N + \frac{\sum_{S_i=1} Y_i}{\gamma}$$
$$\hat{\gamma} = \frac{\sum_{S_i=1} Y_i}{\sum_{S_i=1} 2\mu N}$$

142

Algorithm 1: Procedure for Parameter Estimation

- 1. Set initial configuration S⁰
- 2. In the *j*th iteration, for given $s^{(j-1)}$, obtain $\hat{\theta}_0^j$ from

logit
$$\Pr\left(S_{i}^{(j-1)} \mid S_{N_{i}}^{(j-1)}, \theta_{0}\right) = h + \tau_{1}X_{i1} - \tau_{0}X_{i0}, \ i = 1, \cdots, n$$

3. Sequentially update the labels of nodes to obtain $S^{(j)}$ (ICM)

$$S_{i}^{(j)} = \arg \max_{s_{i}} f\left(Y_{i} \mid S_{i}, \hat{\theta}_{1}^{(j-1)}\right) \Pr\left(S_{i} \mid S_{N_{i}}^{(j-1)}, \hat{\theta}_{0}^{(j)}\right) \prod_{k \in S_{N}} \Pr\left(S_{k}^{(j-1)} \mid S_{i}, S_{N_{k}-i}^{(j-1)}, \hat{\theta}_{0}^{(j)}\right)$$

4. Obtain $\hat{\theta}_1^j(\hat{\gamma}^{(j)})$ from

$$\hat{\theta}_{1}^{(j)} = \operatorname{argmax}_{\theta_{1}} \log L\left(\theta_{1} \mid \theta_{0}^{(j)}, S^{(j)}, Y\right)$$

5. Repeat steps 2, 3, and 4 until convergence

- 145 Finally, after we obtain the estimated $\hat{\theta}_0$ and $\hat{\theta}_1$, we use Gibbs sampling based on the
- 146 conditional distribution $P(S_i | S_{N_i}, \hat{\theta}_0, \hat{\theta}_1)$. This method has been proved to be valid for multiple
- testing under dependence in a compound decision theoretic framework [37, 38]. Then, we can

estimate the marginal posterior probability $q_i = P(S_i = -1|Y)$. Let $q_{(i)}$ be the sorted values of q_i 148 149 in descending order. For each gene i, the null hypothesis and alternative hypothesis are 150 H_{i0} : Gene *i* is not associated with the trait of interest 151 H_{i1} : Gene *i* is associated with the trait of interest 152 As shown by Jiang and Yu [39], the relationship between global FDR and local FDR (lfdr) is 153 $FDR = E(|fdr| Y \in \mathcal{R})$, where the rejection region \mathcal{R} is the set of Y such that the null hypothesis can be rejected based on a specific rejection criterion. To control the expected global FDR less 154 than α , we propose the following procedure: let $m = \max \{s: \frac{1}{s} \sum_{i=1}^{s} q_{(i)}\}$, we reject all the null 155 156 hypotheses corresponding to $H_{(1)}, \ldots, H_{(m)}$. 157 158 **Results** 159 **Simulation Studies** 160 For DNV and network data, we considered similar settings as our real data. We randomly 161 selected 2,000 genes, retrieved their mutability from the real data, and extracted the 162 corresponding PPI network formed by these 2,000 genes. First, we simulated the true model 163 with parameter values similar as those from real data analysis to see whether N-DATA can 164 control FDR. Then, we evaluated the power under various settings of sample sizes N and 165 relative risk parameter γ . 166 167 We set true network parameter θ_0 as (-4, 0.2, 0) to make the total number of risk genes in the 168 network of 2,000 random genes to be around 100. We varied the sample size N at 2,000, 5,000 169 and 10,000 to evaluate the performance of N-DATA in small, medium, and large WES cohorts, 170 respectively. In addition, we varied β (log relative risk parameter γ) at 3.5, 4 and 4.5 to 171 investigate the performance of N-DATA around the burden estimated results from real data (In real data analysis, $\hat{\beta} = 3.60$). Each simulation setting was replicated 100 times. For Gibbs 172

sampling-based inference, we used 2,000 MCMC iterations, and set the first 1,000 iterations as

- 174 burn-ins. These numbers were chosen empirically based on the diagnostic plots for
- 175 convergence. We report the performance under FDR threshold 0.05 in the main text (Fig 2) and
- 176 FDR threshold 0.01 and 0.1 in Additional File 1.
- 177

First, we compared the performance of N-DATA model with and without the PPI network as
input. For N-DATA model without the PPI network, we assigned the weight of gene for
inference. Both models controlled FDR well under all the settings. N-DATA model with PPI
network had much better power than the model without PPI network when the sample size and
were both low. When the sample size and were larger, the power of N-DATA without PPI
network improved as expected.



¹⁸⁴

Fig 2. Comparison of N-DATA w/o and w/ PPI network models. (A) Power comparison of the two models. Three panels from left to right represent cohorts with small, medium, and large sample sizes, respectively. (B) FDR control for the two models. Red dash line represents the preset FDR threshold 0.05. Three panels from left to right represent cohorts with small, medium, and large sample sizes, respectively.

- 189
- 190 Then, we compared the power of TADA-De novo, DAWN, and N-DATA using the same
- 191 parameter settings. Hyperprior of TADA-*De novo* was estimated from the function *denovo.MOM*
- based on the recommendation from the authors [40]. Power of TADA was calculated based on
- 193 TADA q-values. DAWN v1.0 was downloaded from

http://www.compgen.pitt.edu/DAWN/DAWN_homepage.htm. We adapted the code of DAWN to
use adjacency matrices of networks as its input. We used TADA-*De novo* p-values and PPI
network as the input of DAWN. The parameter trim threshold was set to 4 based on the
observation in our real data that, which corresponds to select the top 5 genes in TADA-*De novo*as fixed risk genes.

199

200 We compared the performance of TADA-De novo, TADA-De novo p-values + DAWN and N-201 DATA under different simulation settings. We reported the performance under FDR threshold 202 0.05 in the main text (Fig 3) and FDR threshold 0.01 and 0.1 in Additional File 1. We first 203 checked if all three methods could control the global FDR when the threshold is 0.05. As 204 discussed above, N-DATA controlled FDR well under all settings, while there was slight FDR 205 inflation of TADA-De novo and DAWN under a couple of settings, especially when both and 206 were very small or very large. N-DATA had the best power among the three methods under all 207 settings. With an increase of and , the performance of TADA-De novo and DAWN also 208 became better. For settings with FDR well controlled, DAWN performed better than TADA-De 209 novo.





Fig 3. Comparison of TADA-*De novo*, TADA-*De novo* p-values + DAWN and N-DATA. Error bars represent
 standard errors estimated from 100 replications of simulation. (A) Power comparison of the three methods. Three
 panels from left to right represent cohorts with small, medium, and large sample sizes, respectively. (B) FDR control

for the three methods. Red dash line represents the preset FDR threshold 0.05. Three panels from left to rightrepresent cohorts with small, medium, and large sample sizes, respectively.

216

217 Real Data Applications

218 We applied N-DATA to DNV data from 2,645 CHD trios reported in Jin et al [5]. We only

219 considered damaging variants (loss of function (LoF) and deleterious missense (Dmis) variants

220 by the MetaSVM algorithm) in our analysis as the number of non-deleterious variants is not

221 expected to provide information to differentiate cases from controls biologically [41].

222

223 For network information, we first downloaded STRING v11.0 with medium edge likelihood via 224 interface from STRINGdb package in R, and call this original network from STRING G_0 . We 225 obtained the curated list of known human CHD genes from Jin el al [5] and expanded the gene 226 list by including additional candidate genes (FDR<0.1) from the single-trait analysis in our 227 previous work [32]. Then, we extracted the subnetwork including the aforementioned gene list 228 and the direct neighbors with likelihood score larger than 950 of those genes, and call this subnetwork \mathcal{G}_1 . We only kept overlapping genes with our DNV data in \mathcal{G}_1 and called the final 229 230 network used in our real application as G_2 . There were in total 1,818 genes and 21,534 edges in 231 \mathcal{G}_2 .

232

To show that our method can leverage network information to boost risk gene identification, we applied our algorithm without using the network as an input. When there was no prior information from the network, we identified 18 significant genes with FDR<0.05. To include the network information from G_2 , we denote the degree of gene *i* in network G_2 as d_i , and let the weight in the prior as $w_i = \sqrt{d_i}$ following Chen et al. [19]. After adding the network information from G_2 , we identified 46 genes with at least 1 DNV, and 26 genes harboring at least 2 DNVs with FDR<0.05 in the CHD cohort.

240

241	We also compared our results with TADA-De novo test [40] and DAWN [21, 42]. We
242	downloaded the software of DAWN and adapted its code by substituting the adjacency matrix
243	inferred from its Partial Neighborhood Selection algorithm to the adjacency matrix from network
244	\mathcal{G}_2 . The parameter settings were discussed in the simulation section. Specifically, we also
245	compared two approaches to control the global FDR for TADA-De novo test (FDR q-values and
246	p-values with FDR adjustment). FDR q-values given by TADA-De novo identified 25 significant
247	genes, and p-values with FDR adjustment identified the same 25 genes. After integrating the p-
248	values with the \mathcal{G}_2 network, 36 genes were identified by the adapted DAWN method. In total, N-
249	DATA identified 325 genes with FDR<0.05. As some of the genes may be prioritized due to high
250	prior probability, but did not have DNV count in the study cohort, we further filtered out genes
251	without DNV and considered the 46 genes identified with FDR<0.05 and at least 1 DNV as the
252	candidate genes. (Table 1)

Method	Criteria	Number of Identified Genes
TADA- <i>De novo</i> q-values	FDR<0.05	25
TADA- <i>De novo</i> p-values	FDR<0.05	25
DAWN		
(Network G_2 + TADA- <i>De novo</i> p-	FDR<0.05	36
values)		
N-DATA	FDR<0.05	325
(Network \mathcal{G}_2 network + DNV	■ DNVs≥1	020
counts)		46

253

Table 1. Comparison of N-DATA with other methods

We visualized the overlap of 253 known human CHD genes [5], genes that were identified by TADA-*De novo* q-values, DAWN, and N-DATA in Fig 4. Fig 4A shows the 325 genes identified by N-DATA, while Fig 4B shows the 46 genes with at least 1 DNV. From Fig 4B, N-DATA found all genes that can be identified by TADA, and identified 11 different genes compared with DAWN.

- 260
- Α

TADA TADA+DAWN TADA TADA+DAWN 0 3 0 3 0 0 8 0 8 0 226 281 235 11 0 9 0 9 16 16 0 0 0 0 0 N-DATA N-DATA Known Known 11 2

в

261



Overlapping genes between known human CHD genes, TADA- *De novo*, TADA-*De novo* +DAWN and all 325 genes
 identified by N-DATA. (B) Overlapping genes between known human CHD genes, TADA- *De novo*, TADA-*De novo* +DAWN and 46 candidate genes identified by N-DATA.

266

Among the 46 genes, 18 are known human CHD genes and 35 are in the top 25% in mouse developing heart (HHE) at E14.5 [12]. Further, we calculated the overlap of the 46 N-DATA candidate genes, TADA genes, DAWN genes and 872 HHE genes that were analyzed in the 1,818 gene network. (Fig 5).



272

273 Fig 5. Venn diagram of HHE genes, TADA genes, DAWN genes and the 46 N-DATA candidate genes. N-DATA

274 candidate genes identified 11 additional HHE genes compared with other methods.

275

276 We also visualized these 46 genes in the network to demonstrate that the PPI network

277 information can help boost statistical power and provide biological interpretation.



Fig 6. N-DATA model identified 46 candidate genes with at least 1 DNV. Green labels indicate the 18 genes
identified when no network information was provided for N-DATA, and red labels indicate the additional 28 genes

identified when the G_2 network was integrated. Circles indicate the 18 known human CHD genes, and squares indicate the 28 novel genes identified by N-DATA.

283

284 Among the 46 candidate genes, PTPN11, RAF1 and RIT1 had 2 recurrent DNVs, and CHD7, 285 NOTCH1, NSD1 and PYGL also had recessive genotypes in the CHD cohort [5]. The 46 286 candidate genes form 4 clusters (Fig 6) in the \mathcal{G}_2 network. The biggest cluster includes seven 287 known CHD genes TBX5, KMT2D, PTPN11, SOS1, ACTB, NOTCH1, and PTEN, which are 288 involved in transcriptional regulation and the early cell growth or differentiation processes. The 289 six new genes SMAD2, KLF4, CTNNB1, CDC42, ITSN2, and WWTR1 also function in similar 290 pathways and have varied implications in cardiac development. For instance, KLF4 and 291 CTNNB1 have been implicated in cardiac cell differentiation [43]. Cdc42 cardiomyocyte knock-292 out mice presented heart defects such as ventricular septum defects and thin ventricular walls 293 [44]. WWTR1 encodes a transcription regulator, which serves as an effector of Hippo pathway 294 and regulates cardiac wall maturation in zebrafish [45]. 295

296 The second biggest cluster is constituted of 7 new genes, all of which are involved in mRNA 297 splicing. Specifically, SART1, SRRM2, PRPF38A, PRPF8, and SF3B1 are associated factors or 298 components of spliceosome; HNRNPK encodes a pre-mRNA-binding protein; DHX9 encodes 299 an RNA helicase which promotes R-loop formation while RNA splicing is perturbed [46]. 300 Alternative splicing plays an essential role in heart development, homeostasis, and disease 301 pathogenesis. Mouse knockouts of multiple splice factors had impaired cardiogenesis [47]. 302 SF3B1, specifically, has been shown to upregulate to induce heart disease in both human and 303 mice [48]. Thus, though not fully investigated, DNVs in those mRNA splicing-related genes may 304 contribute to CHD pathogenesis.

305

306 The third cluster contains genes involved in protein synthesis, includes the known gene RPL5 307 and genes not previously associated with CHD (EIF4, EIF5, EEF2, and RPL10). RPL5 and 308 RPL10 encode the ribosome subunits. Mutations in RPL5 and other ribosomal genes can lead 309 to multiple congenital anomalies, including CHD [49]. EIF4 and EIF5 encode translation initiation 310 factors while *EEF2* encodes the elongation factor that regulate peptide chain elongation during 311 protein synthesis. A recent study reported that the deficiency in ribosome associated NatA 312 complex reduces ribosomal protein and subsequently impact cell development as a mechanism 313 to cause CHD [50]. Thus, DNVs in the above genes may lead to CHD via impairment of protein 314 synthesis. 315 316 The last cluster contains the known CHD genes *BRAF* and *RAF1*, both of which encode key 317 kinases in Ras signaling and are related to Noonan syndrome with CHD as a common feature. 318 319 Among the un-clustered genes, six are identified after using the network information: ABCE1, 320 UBE2B, SDC1, PYGL, KDM5B, MED20. UBE2B and KDM5B, encoding epigenetic modifiers, 321 have shown suggestive evidence in cardiac development or CHD [51] [52] and might be 322 potential CHD genes. 323 324 Discussion

In this article, we have introduced a Bayesian framework to integrate PPI network information as the prior knowledge into DNV analysis for CHD. This approach adopts MRF to model the interactions among genes. We apply an empirical Bayes strategy to estimate parameters in the model and conduct statistical inference based on the posterior distribution sampled from a Gibbs sampler. The simulation studies and real data analysis on CHD suggest that the proposed method has improved power to identify risk genes over methods without integrating network information.

332

354	Conclusions
353	
352	functional annotation of variants as a layer in the model to further improve statistical power.
351	across variants with different functions (e.g., LoF and Dmis). Future studies may explore adding
350	is the same across all genes in N-DATA, which may cause our model to lose power if it varies
349	ins. In addition, we only considered damaging DNVs and assumed the relative risk parameter $\boldsymbol{\gamma}$
348	suggest running at least 2,000 times of iterations and discard the first 1,000 iterations as burn-
347	Gibbs sampler tends to move around local maxima for some time before convergence. We
346	the labels of genes from a known risk gene set or run with multiple starts. Also, we observe the
345	likelihood-based inference may suffer from local maxima [19]. Thus, we recommend to initiate
344	association test in the network like our motivating example. Another limitation is that the
343	important to conduct an initial analysis on the enrichment of top genes identified from de novo
342	However, there are some limitations in the current N-DATA model. In real application, it is
341	
340	visualizing clusters of risk genes with functional relevance in the network.
339	only increase power in risk gene identification, but will also assist in biological interpretation by
338	database instead, which makes it more applicable to different diseases. This method will not
337	not require external expression data for the DNV cohort and uses the publicly available PPI
336	other sources compared to the existing pathway-based test for DNV data [17, 31]. Third, it does
335	from other DNV association software. Second, it does not need to estimate hyperprior based on
334	disease-associated genes using a network-based model without relying on summary statistics
333	Our proposed framework is innovative for the following aspects. First, it can directly infer

The topologic information in a pathway may be informative to identify functionally interrelated genes and help improve statistical power in DNV studies. Under the hypothesis that connected genes in PPI networks are more likely to share similar disease association status, we developed

- a novel statistical model that can leverage information from publicly available PPI databases.
- 359 Through simulation studies under multiple settings, we proved our method can increase
- 360 statistical power in identifying additional risk genes compared to methods without using the PPI
- 361 network information. We then applied our method to the CHD DNV data, and then visualized the
- 362 subnetwork of candidate genes to find potential functional gene clusters for CHD. Our results
- 363 may shed new insight on the shared protein functionality among risk genes for CHD.
- 364
- 365 List of abbreviations
- 366 DNV: *de novo* variant
- 367 CHD: congenital heart disease
- 368 WES: Whole Exome Sequencing
- 369 PPI: protein-protein Interaction
- 370 FDR: false discovery rate
- 371 MRF: Markov Random Field
- 372 GWAS: Genome-Wide Association Studies
- 373

374 References

- 3751.Zaidi S, Choi M, Wakimoto H, Ma L, Jiang J, Overton JD, Romano-Adesman A, Bjornson376RD, Breitbart RE, Brown KK, et al: De novo mutations in histone-modifying genes in377congenital heart disease. Nature 2013, 498:220-223.
- Postma AV, Bezzina CR, Christoffels VM: Genetics of congenital heart disease: the
 contribution of the noncoding regulatory genome. *Journal of Human Genetics* 2016,
 61:13-19.
- Sevim Bayrak C, Zhang P, Tristani-Firouzi M, Gelb BD, Itan Y: De novo variants in exomes
 of congenital heart disease patients identify risk genes and pathways. *Genome Med* 2020, 12:9.
- Diab NS, Barish S, Dong W, Zhao S, Allington G, Yu X, Kahle KT, Brueckner M, Jin SC:
 Molecular Genetics and Complex Inheritance of Congenital Heart Disease. *Genes* (*Basel*) 2021, 12.

387 388 389	5.	Jin SC, Homsy J, Zaidi S, Lu Q, Morton S, DePalma SR, Zeng X, Qi H, Chang W, Sierant MC, et al: Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands. <i>Nat Genet</i> 2017, 49: 1593-1601.
390 391	6.	Zaidi S, Brueckner M: Genetics and Genomics of Congenital Heart Disease. Circ Res 2017, 120:923-940.
392 393 394	7.	Glessner JT, Bick AG, Ito K, Homsy J, Rodriguez-Murillo L, Fromer M, Mazaika E, Vardarajan B, Italia M, Leipzig J, et al: Increased frequency of de novo copy number variants in congenital heart disease by integrative analysis of single nucleotide
395		polymorphism array and exome sequence data. <i>Circ Res</i> 2014, 115 :884-896.
396 397 398	8.	Soemedi R, Wilson IJ, Bentham J, Darlay R, Töpf A, Zelenika D, Cosgrove C, Setchfield K, Thornborough C, Granados-Riveron J, et al: Contribution of global rare copy-number variants to the risk of sporadic congenital heart disease. <i>Am J Hum Genet</i> 2012, 01:480-501
399	٥	91:469-301. Diarnant ME Bruacknar M. Chung W/K. Garg V. Jacro PV. McGuiro Al, Mital S. Briast IP
400	Э.	Pu WT Roberts A et al: Genetic Basis for Congenital Heart Disease: Revisited: A
402		Scientific Statement From the American Heart Association Circulation 2018 138:e653-
402		
404	10	Teer IK Mullikin IC: Exome sequencing: the sweet spot before whole genomes. Human
405	10.	Molecular Genetics 2010 19:R145-R151.
406	11.	Rabbani B. Tekin M. Mahdieh N: The promise of whole-exome sequencing in medical
407		genetics. Journal of Human Genetics 2014. 59:5-15.
408	12.	Homsy J. Zaidi S. Shen Y. Ware JS. Samocha KE. Karczewski KJ. DePalma SR. McKean D.
409		Wakimoto H, Gorham J, et al: De novo mutations in congenital heart disease with
410		neurodevelopmental and other congenital anomalies. Science 2015, 350:1262-1266.
411	13.	Richter F, Morton SU, Kim SW, Kitaygorodsky A, Wasson LK, Chen KM, Zhou J, Qi H, Patel
412		N, DePalma SR: Genomic analyses implicate noncoding de novo variants in congenital
413		heart disease. Nature genetics 2020, 52:769-777.
414	14.	Watkins WS, Hernandez EJ, Wesolowski S, Bisgrove BW, Sunderland RT, Lin E, Lemmon
415		G, Demarest BL, Miller TA, Bernstein D: De novo and recessive forms of congenital
416		heart disease have distinct genetic and phenotypic landscapes. <i>Nature</i>
417		communications 2019, 10 :1-12.
418	15.	Sifrim A, Hitz M-P, Wilsdon A, Breckpot J, Turki SHA, Thienpont B, McRae J, Fitzgerald
419		TW, Singh T, Swaminathan GJ, et al: Distinct genetic architectures for syndromic and
420		nonsyndromic congenital heart defects identified by exome sequencing. <i>Nature</i>
421		Genetics 2016, 48:1060-1065.
422	16.	Sifrim A, Hitz MP, Wilsdon A, Breckpot J, Turki SH, Thienpont B, McRae J, Fitzgerald TW,
423		Singh T, Swaminathan GJ, et al: Distinct genetic architectures for syndromic and
424		nonsyndromic congenital heart defects identified by exome sequencing. Nat Genet
425		2016, 48 :1060-1065.
426	17.	Nguyen TH, He X, Brown RC, Webb BT, Kendler KS, Vladimirov VI, Riley BP, Bacanu SA:
427		DECO: a framework for jointly analyzing de novo and rare case/control variants, and
428		biological pathways. Brief Bioinform 2021.

429 Lee I, Blom UM, Wang PI, Shim JE, Marcotte EM: Prioritizing candidate disease genes by 18. 430 network-based boosting of genome-wide association data. Genome Res 2011, 21:1109-431 1121. 432 19. Chen M, Cho J, Zhao H: Incorporating biological pathways via a Markov random field 433 model in genome-wide association studies. PLoS Genet 2011, 7:e1001353. 434 Hou L, Chen M, Zhang CK, Cho J, Zhao H: Guilt by rewiring: gene prioritization through 20. 435 network rewiring in genome wide association studies. Hum Mol Genet 2014, 23:2780-436 2790. 437 21. Liu L, Lei J, Roeder K: Network assisted analysis to reveal the genetic basis of autism. 438 The Annals of Applied Statistics 2015, 9:1571-1600, 1530. 439 Nguyen HT, Bryois J, Kim A, Dobbyn A, Huckins LM, Munoz-Manchado AB, Ruderfer DM, 22. 440 Genovese G, Fromer M, Xu X, et al: Integrated Bayesian analysis of rare exonic variants 441 to identify risk genes for schizophrenia and neurodevelopmental disorders. Genome 442 Med 2017, 9:114. 443 23. Nguyen T-H, Dobbyn A, Brown RC, Riley BP, Buxbaum JD, Pinto D, Purcell SM, Sullivan PF, 444 He X, Stahl EA: mTADA is a framework for identifying risk genes from de novo 445 mutations in multiple traits. Nature Communications 2020, 11:2929. 446 Oughtred R, Stark C, Breitkreutz BJ, Rust J, Boucher L, Chang C, Kolas N, O'Donnell L, 24. 447 Leung G, McAdam R, et al: The BioGRID interaction database: 2019 update. Nucleic 448 Acids Res 2019, **47**:D529-d541. 449 Orchard S, Ammari M, Aranda B, Breuza L, Briganti L, Broackes-Carter F, Campbell NH, 25. 450 Chavali G, Chen C, del-Toro N, et al: The MIntAct project--IntAct as a common curation 451 platform for 11 molecular interaction databases. Nucleic Acids Res 2014, 42:D358-363. 452 Salwinski L, Miller CS, Smith AJ, Pettit FK, Bowie JU, Eisenberg D: The Database of 26. 453 Interacting Proteins: 2004 update. Nucleic Acids Res 2004, 32:D449-451. 454 Licata L, Briganti L, Peluso D, Perfetto L, Iannuccelli M, Galeota E, Sacco F, Palma A, 27. 455 Nardozza AP, Santonico E, et al: MINT, the molecular interaction database: 2012 456 update. Nucleic Acids Res 2012, 40:D857-861. Mishra GR, Suresh M, Kumaran K, Kannabiran N, Suresh S, Bala P, Shivakumar K, 457 28. 458 Anuradha N, Reddy R, Raghavan TM, et al: Human protein reference database--2006 459 update. Nucleic Acids Res 2006, 34:D411-414. 460 Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, 29. Doncheva NT, Morris JH, Bork P, et al: STRING v11: protein-protein association 461 462 networks with increased coverage, supporting functional discovery in genome-wide 463 experimental datasets. Nucleic Acids Res 2019, 47:D607-d613. 464 30. Nguyen TH, Dobbyn A, Brown RC, Riley BP, Buxbaum JD, Pinto D, Purcell SM, Sullivan PF, 465 He X, Stahl EA: mTADA is a framework for identifying risk genes from de novo mutations in multiple traits. Nat Commun 2020, 11:2929. 466 Nguyen HT, Dobbyn A, Charney AW, Bryois J, Kim A, Mcfadden W, Skene NG, Huckins 467 31. 468 LM, Wang W, Ruderfer DM, et al: Integrative analysis of rare variants and pathway 469 information shows convergent results between immune pathways, drug targets and 470 epilepsy genes. bioRxiv 2018:410100. 471 32. Xie Y, Li M, Dong W, Jiang W, Zhao H: M-DATA: A statistical approach to jointly 472 analyzing de novo mutations for multiple traits. PLoS Genet 2021, 17:e1009849.

473 474	33.	Kindermann R: Markov random fields and their applications. American mathematical
4/4 475	24	Society 1960.
475	54.	Samocha KE, Robinson EB, Sanders SJ, Stevens C, Sabo A, McGrath Livi, Rosinicki JA,
470		mutation in human disease. Nat Const 2014 46:044.050
4// 170	25	Possa I: On the statistical analysis of dirty nictures, Journal of the Poyal Statistical
470 170	55.	Society: Series B (Methodological) 1986 18 :259-279
475	36	Le Cessie S. Van Houwelingen IC: Bidge estimators in logistic regression Journal of the
480	50.	Royal Statistical Society: Series C (Applied Statistics) 1992 A1 :191-201
401	27	Sun W. Tony Cai T. Largo - scale multiple testing under dependence. Journal of the
40Z 192	57.	Poyal Statistical Society: Series B (Statistical Methodology) 2009 71 :202 A24
405	20	Li H. Woi Z. Maris I: A hidden Markey random field model for genome-wide association
404 105	50.	studios <i>Piostatistics</i> 2010, 11:120, 150
405	20	liang W/ Yu W/: Controlling the joint local false discovery rate is more new offul than
480	55.	mata-analysis methods in joint analysis of summary statistics from multiple genema-
407 100		wide association studies. <i>Disinformatics</i> 2016, 22 :E00, E07
400 190	40	He X Sandors SL Liu L De Pubeis S Lim ET Sutcliffe IS Schollenberg CD Gibbs PA Daly
409	40.	ML Buybaum ID, at al: Integrated model of do nove and inherited genetic variants
490		violds groater newer to identify risk gapos <i>PLoS Gapat</i> 2013 9 :01002671
491	/11	Li M: Gana-based Association Analysis for Ganama-wide Association and Whole-
492	41.	exome Sequencing Studies. Vale University, Piectatistics, 2020
495	10	Line Loid Sandors SL Willson AL Kou V Cisck AE Kloid Lu C Ho V Li M at al: DAWN: a
494	42.	framework to identify autism genes and subnetworks using gene expression and
495		gonotics Mol Autism 2014 5:22
490	12	geneucs. Mol Autism 2014, 5.22. Kami D. Kitani T. Kawasaki T. Goio S: Cardiac mesonchymal progenitors differentiate
497	45.	into adinacytos via Klf4 and c-Myc. Cell death & disease 2016. 7:02100 02100
490	11	Liu V. Wang L. Li L. Wang P. Tharakan P. Zhang SL. Tong CW. Bong V: Dolotion of Cdc/2 in
499 500	44.	embryonic cardiomyocytos results in right yontricle hypoplasia. <i>Clinical and</i>
500		translational medicine 2017 6:40 40
501	15	Lai IKH Colling MM Uribo V limónoz Amilhuru V Günthor S. Maischoin HM Stainiar
502	45.	DVP: The Hinne nathway offector West regulates cardiac wall maturation in
504		zohrafish Development 2018 145
504	16	Chakraberty P. Huang ITI. Hiem K: DHY9 belicase promotes P-loop formation in cells
505	40.	with impaired PNA colicing. Nat Commun 2019, 9:4246
507	47	Zahr HC, Jaalouk DE: Evoloring the Crosstalk Between LMNA and Splicing Machinery
502	47.	Gono Mutations in Dilated Cardiomyonathy, Front Ganet 2018, 9:231
500	10	Van den Heegenhef MM. Pinte VM. Creemers EE: PNA Splicing: Pegulation and
510	40.	Dysregulation in the Heart Circ Res 2016 118:454-468
510	10	Gazda HT, Shoon MP, Vlachos A, Choosmol V, O'Donobuo ME, Schneider H, Darras N
512	чЭ.	Hasman C Sieff CA Newhurger PE et al. Rihosomal protein 15 and 111 mutations are
512		associated with cleft nalate and abnormal thumbs in Diamond-Blackfan anomia
517		nationts Am I Hum Genet 2008 83.769.780
514		parents. Ani j num Genet 2000, 03.700.

515 50. Ward T, Tai W, Morton S, Impens F, Van Damme P, Van Haver D, Timmerman E, 516 Venturini G, Zhang K, Jang MY, et al: Mechanisms of Congenital Heart Disease Caused 517 by NAA15 Haploinsufficiency. Circ Res 2021, 128:1156-1169. 518 51. Robson A, Makova SZ, Barish S, Zaidi S, Mehta S, Drozd J, Jin SC, Gelb BD, Seidman CE, 519 Chung WK, et al: Histone H2B monoubiguitination regulates heart development via 520 epigenetic control of cilia motility. Proc Natl Acad Sci U S A 2019, **116**:14049-14054. 521 52. Audain E, Wilsdon A, Breckpot J, Izarzugaza JMG, Fitzgerald TW, Kahlert AK, Sifrim A, 522 Wünnemann F, Perez-Riverol Y, Abdul-Khaliq H, et al: Integrative analysis of genomic 523 variants reveals new associations of candidate haploinsufficient genes with congenital 524 heart disease. PLoS Genet 2021, 17:e1009679.

525

526 Acknowledgements

- 527 We thank Jin et al. [5] for sharing the *de novo* variant data of CHD. We thank Andrew Xu and Dr.
- 528 Min Chen for discussions on coding, and Ziyu Jiang for discussions on diagnostic for Bayesian
- 529 inference.
- 530
- 531 Funding
- 532 This work was supported in part by NIH grant R03HD100883-01A1 (Y.X. and H.Z.) and
- 533 R01GM134005-01A1 (W.J., H.L., and H.Z.). The funders had no role in study design, data
- 534 collection and analysis, decision to publish, or preparation of the manuscript.

535

536 Ethics Declaration

537 Ethics approval and consent to participate

- 538 This manuscript is a mainly methodology paper. The data used in this manuscript is all public
- available. The research has no procedure related to collecting human subject data.
- 540 **Consent for publication**
- 541 Not applicable.
- 542 Competing interests
- 543 The authors declare that they have no competing interests.

544 Supplementary Information

545 Additional File 1. Supplementary figures 1-4